HTR1A and psychotic disorder: Our study demonstrates for the first time to our knowledge that an experimental model induces the same dopaminergic phenotype seen in patients with psychosis, and the potential of targeting PV interneurons and a novel TAAR1/5HT1A agonist to reverse the dopaminergic phenotype.